The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Angina Pectoris

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Angina Pectoris

 

Psychiatry related information on Angina Pectoris

 

High impact information on Angina Pectoris

 

Chemical compound and disease context of Angina Pectoris

 

Biological context of Angina Pectoris

 

Anatomical context of Angina Pectoris

 

Gene context of Angina Pectoris

  • IL-6 and interferon-gamma were detected in 17.4%, and tumor necrosis factor-alpha in 13.0% of patients with acute myocardial infarction, but the frequency was not statistically significantly different from that in angina pectoris [23].
  • Serum levels of soluble P-selectin, ICAM-1 and VCAM-1 are elevated in patients with angina pectoris or peripheral atherosclerotic disease [24].
  • Plasminogen activator inhibitor-I antigen level decreased significantly between day 2 and 19, then returned to the baseline levels of patients with angina pectoris nearly 4 weeks later [25].
  • We therefore studied the interrelationships between PAI-1, plasma insulin, and acute-phase proteins in 67 patients with angina pectoris [26].
  • Patients with initial AMI had significantly higher levels of t-PA activity than those of 14 patients with angina pectoris [25].
 

Analytical, diagnostic and therapeutic context of Angina Pectoris

References

  1. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Thompson, S.G., Kienast, J., Pyke, S.D., Haverkate, F., van de Loo, J.C. N. Engl. J. Med. (1995) [Pubmed]
  2. Nifedipine-induced hypotension and myocardial ischemia in refractory angina pectoris. Boden, W.E., Korr, K.S., Bough, E.W. JAMA (1985) [Pubmed]
  3. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. Rapola, J.M., Virtamo, J., Haukka, J.K., Heinonen, O.P., Albanes, D., Taylor, P.R., Huttunen, J.K. JAMA (1996) [Pubmed]
  4. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Juul-Möller, S., Edvardsson, N., Jahnmatz, B., Rosén, A., Sørensen, S., Omblus, R. Lancet (1992) [Pubmed]
  5. A possible role for propranolol in the treatment of renal osteodystrophy. Caro, J.F., Besarab, A., Burke, J.F., Glennon, J.A. Lancet (1978) [Pubmed]
  6. Patient compliance and therapeutic coverage: amlodipine versus nifedipine (slow-release) in the treatment of angina pectoris. Belgian Collaborative Group. Detry, J.M., Block, P., De Backer, G., Degaute, J.P., Six, R. J. Int. Med. Res. (1994) [Pubmed]
  7. Nitrate therapy for stable angina pectoris. Parker, J.D., Parker, J.O. N. Engl. J. Med. (1998) [Pubmed]
  8. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. Parker, J.O., Farrell, B., Lahey, K.A., Moe, G. N. Engl. J. Med. (1987) [Pubmed]
  9. Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. Robertson, R.M., Robertson, D., Roberts, L.J., Maas, R.L., FitzGerald, G.A., Friesinger, G.C., Oates, J.A. N. Engl. J. Med. (1981) [Pubmed]
  10. Molsidomine in the treatment of patients with angina pectoris. Majid, P.A., DeFeyter, P.J., Van der Wall, E.E., Wardeh, R., Roos, J.P. N. Engl. J. Med. (1980) [Pubmed]
  11. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. Thadani, U., Davidson, C., Singleton, W., Taylor, S.H. N. Engl. J. Med. (1979) [Pubmed]
  12. Nitroglycerin for angina pectoris. Copelan, H.W. JAMA (1978) [Pubmed]
  13. Combined propranolol and digoxin therapy in angina pectoris. Crawford, M.H., LeWinter, M.M., O'Rourke, R.A., Karliner, J.S., Ross, J. Ann. Intern. Med. (1975) [Pubmed]
  14. Increased exercise tolerance after nitroglycerin oral spray: a new and effective therapeutic modality in angina pectoris. Kimchi, A., Lee, G., Amsterdam, E., Fujii, K., Krieg, P., Mason, D.T. Circulation (1983) [Pubmed]
  15. Heart rate and arterial blood pressure during exercise in patients with angina pectoris. Effects of training and of nitroglycerin. Clausen, J.P., Trap-Jensen, J. Circulation (1976) [Pubmed]
  16. Atenolol: once-daily cardioselective beta blockade for angina pectoris. Jackson, G., Schwartz, J., Kates, R.E., Winchester, M., Harrison, D.C. Circulation (1980) [Pubmed]
  17. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Murata, M., Matsubara, Y., Kawano, K., Zama, T., Aoki, N., Yoshino, H., Watanabe, G., Ishikawa, K., Ikeda, Y. Circulation (1997) [Pubmed]
  18. Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Bergman, G., Daly, K., Atkinson, L., Rothman, M., Richardson, P.J., Jackson, G., Jewitt, D.E. Lancet (1981) [Pubmed]
  19. Myocardial perfusion scintigraphy in patients with mitral valve prolapse: Its advantage over stress electrocardiography in diagnosing associated coronary artery disease and its implications for the etiology of chest pain. Massie, B., Botvinick, E.H., Shames, D., Taradash, M., Werner, J., Schiller, N. Circulation (1978) [Pubmed]
  20. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. Frishman, W.H., Pepine, C.J., Weiss, R.J., Baiker, W.M. J. Am. Coll. Cardiol. (1995) [Pubmed]
  21. Comparative effects of glyceryl trinitrate on venous and arterial smooth muscle in vitro; relevance to antianginal activity. Mackenzie, J.E., Parratt, J.R. Br. J. Pharmacol. (1977) [Pubmed]
  22. Usefulness of intramyocardial injection of autologous bone marrow-derived mononuclear cells in patients with severe angina pectoris and stress-induced myocardial ischemia. Beeres, S.L., Bax, J.J., Kaandorp, T.A., Zeppenfeld, K., Lamb, H.J., Dibbets-Schneider, P., Stokkel, M.P., Fibbe, W.E., de Roos, A., van der Wall, E.E., Schalij, M.J., Atsma, D.E. Am. J. Cardiol. (2006) [Pubmed]
  23. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. Matsumori, A., Furukawa, Y., Hashimoto, T., Yoshida, A., Ono, K., Shioi, T., Okada, M., Iwasaki, A., Nishio, R., Matsushima, K., Sasayama, S. J. Mol. Cell. Cardiol. (1997) [Pubmed]
  24. Adhesion molecules and atherogenesis. Huo, Y., Ley, K. Acta Physiol. Scand. (2001) [Pubmed]
  25. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction. Yamada, S., Yamada, R., Ishii, A., Ashikawa, K., Kawamitsu, H., Fujita, K. Journal of cardiology. (1996) [Pubmed]
  26. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Juhan-Vague, I., Alessi, M.C., Joly, P., Thirion, X., Vague, P., Declerck, P.J., Serradimigni, A., Collen, D. Arteriosclerosis (1989) [Pubmed]
  27. Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance. Thadani, U., Hamilton, S.F., Olson, E., Anderson, J., Voyles, W., Prasad, R., Teague, S.M. Ann. Intern. Med. (1986) [Pubmed]
  28. Effects of acebutolol on chronic stable angina pectoris. A placebo-controlled, double-blind, randomized crossover study. DiBianco, R., Singh, S., Singh, J.B., Katz, R.J., Bortz, R., Gottdiener, J.S., Spodick, D.H., Laddu, A.R., Fletcher, R.D. Circulation (1980) [Pubmed]
  29. Increased exercise tolerance and reduced electrocardiographic ischemia with diltiazem in patients with stable angina pectoris. Wagniart, P., Ferguson, R.J., Chaitman, B.R., Achard, F., Benacerraf, A., Delanguenhagen, B., Morin, B., Pasternac, A., Bourassa, M.G. Circulation (1982) [Pubmed]
  30. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Thadani, U., Zellner, S.R., Glasser, S., Bittar, N., Montoro, R., Miller, A.B., Chaitman, B., Schulman, P., Stahl, A., DiBianco, R. Circulation (1991) [Pubmed]
  31. Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina. Camici, P., Araujo, L.I., Spinks, T., Lammertsma, A.A., Kaski, J.C., Shea, M.J., Selwyn, A.P., Jones, T., Maseri, A. Circulation (1986) [Pubmed]
 
WikiGenes - Universities